Insights from 2023 ASH Annual Meeting
A

ASH 2023 Insights: "CAR T-Cell Therapy in Aggressive Lymphomas - Identifying Prognostic and Predictive Markers"

By Insights from 2023 ASH Annual Meeting FEATURING Anna Sureda
By Insights from 2023 ASH Annual Meeting FEATURING Anna Sureda
72 views
January 8, 2024
0 Comments
Login to view comments. Click here to Login

Featured Video

11:12
Stemline

A proven CD123 targeted therapy for BPDCN

Feat. H. Erba

Featured Video

16:26
Incyte

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Feat. C. Harrison

Related Content

AUTOPLAY
Moffitt Cancer Center

2024 Cell Coast Conference

Fri, Oct 25, 2024
13:07
Moffitt Cancer Center

R/R DLBCL: Are Bispecific Antibodies Superior to CAR-T?

Feat. J. Chavez
27:47
Indy Hematology Review

Current Advances in the Treatment of Aggressive B- and T-Cell Lympho…

Feat. S. Smith
35:27
Louisville Hematology Highlights

Updates on Management of DLBCL

Feat. J. Leonard
10:04
Tara Graff

How to Incorporate Bispecific Antibodies Into Your NHL Practice: A P…

20:34
UChicago Medicine

Sequencing of Bispecifics With Other Therapies in DLBCL

Feat. E. Budde
20:18
XIV Eurasian Hematology-Oncology Congress - EHOC 2023

Will Immune Therapy Replace Transplant in Hematologic Malignancies?

Feat. R. Gale
08:23
Total Health

R/R DLBCL Case Discussion: 81 y/o Male Needing 3rd Line Treatment

Feat. J. Chandler, B. Randolph, M. Onciu
09:18
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Primary OS Analysis of the Phase 3 Random…

Feat. J. Westin
30:07
Dipenkumar Modi

Current Management of DLBCL From Frontline to Relapsed Disease

15:26
Moffitt Cancer Center

R/R DLBCL: Are CAR-Ts Superior to Bispecific Antibodies?

Feat. A. Lazaryan
22:36
UChicago Medicine

Understanding CRISPR and Gene Editing in the Treatment of Heme Malig…

Feat. A. Cooper
14:01
2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Highlights in Heme Malignancies

Feat. M. Gomes da Silva
20:18
Stanford Medicine

Risk of Second Malignancies and T-Cell Lymphoma After CAR T-Cell The…

Feat. M. Hamilton
08:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Outpatient Management of CAR-T and Bi-Speci…

Feat. R. Bansal
45:27
University of Colorado Department of Medicine

Cellular Therapy in 2024: What, Why, When, Who… and Where Are We Goi…

Feat. J. Gutman
62:02
UChicago Medicine

New Treatment Strategies in DLBCL

Feat. L. Sehn
04:08
GRACE

CAR T-Cell Therapy Side Effects for Blood Cancers

Feat. A. Goodman
16:03
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: The New Algorithm for 2L LBCL

Feat. J. Westin
28:10
Indy Hematology Review

2024 Updates on Understanding & Managing Immune Effector Cell To…

Feat. D. Reeves
25:22
Integrity CE

Treatment Updates and Management of Non-Hodgkin Lymphomas

Feat. D. Wallace, M. Cortese